All In Biotech

Drug Trial Radar · NCT03121638

Safety Study of NBP608 in Healthy Adult Volunteers

An Open Label, Active Controlled, Parallel Group Phase I Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of NBP608 in Healthy Adult Volunteers

Last checked: Nov 19, 2026Latest source record: Apr 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

150

Actual

Start

Nov 2012

Primary completion

Feb 2013

Study completion Mar 2013

Sponsor

Lead sponsor
SK Chemicals Co., Ltd.Industry
Sponsor type
Industry
First posted
Apr 20, 2017

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Prevention
FDA-regulated drug
No
Who can join
All sexes, from 20 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

* Indication: Protection against varicella and herpes zoster * Study Objectives * Primary: Safety and tolerability assessment after single dose administration of NBP608 * Secondary: immunogenicity assessment after single dose administration of NBP608

Conditions

  • Varicella Zoster
  • Immunization; Infection

Interventions

  • VARIVAXBiological

    Preparation of Oka/Merck strain of live, attenuated varicella zoster virus

  • ZOSTAVAXBiological

    Preparation of Oka/Merck strain of live, attenuated varicella zoster virus

  • NBP6081Biological

    Preparation of Oka/SK strain of live, attenuated varicella zoster virus

  • NBP6082Biological

    Preparation of Oka/SK strain of live, attenuated varicella zoster virus

  • NBP6083Biological

    Preparation of Oka/SK strain of live, attenuated varicella zoster virus

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence Rate of Adverse EventTime frame: 42days after Investigation Product Vaccination

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Korea University Guro Hospital

    Seoul, South Korea

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.